Intraperitoneal administration of recombinant human growth hormone in children with end-stage renal disease

• Published in: Pediatric nephrology (Berlin, West) Vol. 16; no. 1; pp. 29 - 34
• Main Authors: Gipson, Debbie S., Kausz, Annamaria T., Striegel, Jane E., Melvin, Tyrone R., Astrom, Linda J., Watkins, S. L.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Heidelberg Springer 01.01.2001; Springer Nature B.V
• Subjects: Adolescent; Biological and medical sciences; Child; Child Development; Child, Preschool; Female; Hormones. Endocrine system; Human Growth Hormone - administration & dosage; Human Growth Hormone - adverse effects; Human Growth Hormone - pharmacokinetics; Human Growth Hormone - therapeutic use; Humans; Injections, Intraperitoneal; Kidney Failure, Chronic - drug therapy; Kidney Failure, Chronic - physiopathology; Kidney Failure, Chronic - therapy; Male; Medical sciences; Nutritional Status; Peritoneal Dialysis; Pharmacology. Drug treatments; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - pharmacokinetics; Recombinant Proteins - therapeutic use; Safety; Human; Kidney disease; Intraperitoneal administration; Urinary system disease; Treatment efficiency; Renal failure; Somatotropin hormone; Terminal stage; Growth defect; Child
• ISSN: 0931-041X; 1432-198X
• DOI: 10.1007/s004670000430

Recombinant human growth hormone (GH) therapy has been shown to be effective in the treatment of growth failure related to growth hormone resistance among children with chronic renal failure. The traditional route of administration is subcutaneous injection. This study was designed to evaluate the effectiveness and tolerability of intraperitoneal (i.p.) administration of GH in prepubertal peritoneal dialysis patients. Nine subjects were enrolled. Eight completed 24 months of therapy with GH. Baseline height standard deviation scores (SDS) and growth velocity for the prior year were used for comparison. Peak serum GH was achieved 4 h after administration and serum half-life was 4.6 h. Mean height SDS was -3.1 at baseline, -2.5 at 1 year, and -2.3 at 2 years (NS) of GH therapy. Mean height velocity increased from a baseline of 4.6 cm/yr to 8.5 cm/yr in year 1 (P < 0.05) and 6.1 cm/yr in year 2 (NS) of i.p. GH therapy. Peritonitis infection rates were not increased from overall center rates. This research suggests that the intraperitoneal route of administration of GH can be utilized in the treatment of short stature among children requiring maintenance peritoneal dialysis therapy.